Revvity, Inc.

RVTY

US7140461093

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 04:00:02 2025-06-13 pm EDT			5-day change	1st Jan Change
93.53 ^USD	-2.27%		+3.35%	-16.20%

Jun. 10	Revvity, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08:00 AM
Jun. 02	Revvity, Inc. Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows	CI

Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook

Published on 04/28/2025 at 11:35

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Revvity, Inc.

Revvity, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08:00 AM	Jun. 10
Revvity, Inc. Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows	Jun. 02	CI
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing	May. 19	CI
Revvity, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09:20 AM	May. 13
Tranche Update on Revvity, Inc.'s Equity Buyback Plan announced on November 4, 2024.	May. 06	CI
Mettler-Toledo lowers annual profit forecast on tariff impact	May. 01	RE
UBS Upgrades Revvity to Buy from Neutral, Cuts Price Target to $115 From $145	May. 01	MT
KeyBanc Adjusts Revvity's Price Target to $135 From $145	Apr. 30	MT
Baird Adjusts Price Target on Revvity to $125 From $127, Maintains Outperform Rating	Apr. 29	MT
Raymond James Adjusts Price Target on Revvity to $120 From $145, Maintains Outperform Rating	Apr. 29	MT
JPMorgan Adjusts Price Target on Revvity to $100 From $120, Maintains Neutral Rating	Apr. 29	MT
KeyBanc Adjusts Price Target on Revvity to $145 From $135, Maintains Overweight Rating	Apr. 29	MT
TD Cowen Adjusts Price Target on Revvity to $126 From $122, Maintains Buy Rating	Apr. 29	MT
Goldman Sachs Adjusts Price Target on Revvity to $125 From $140, Maintains Buy Rating	Apr. 29	MT
Jefferies Cuts Price Target on Revvity to $106 From $130	Apr. 28	MT
Citigroup Cuts Price Target on Revvity to $135 From $155	Apr. 28	MT
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook	Apr. 28	RE
Evercore ISI Adjusts Price Target on Revvity to $116 From $125	Apr. 28	MT
Sector Update: Health Care Stocks Mixed Premarket Monday	Apr. 28	MT
Sector Update: Health Care	Apr. 28	MT
The bulls are hanging on!	Apr. 28
Revvity, Inc., Q1 2025 Earnings Call, Apr 28, 2025	Apr. 28
Stocks Decline Pre-Bell as Investors Brace For Big Tech Earnings, Key Economic Data	Apr. 28	MT
Revvity, Inc. Reports Earnings Results for the First Quarter Ended March 30, 2025	Apr. 28	CI
Revvity Q1 Adusted Earnings, Revenue Increase; 2025 Revenue Outlook Lifted	Apr. 28	MT

Revvity, Inc. (formerly PerkinElmer, Inc.) specializes in designing, manufacturing, and marketing measurement devices and analytical instruments for the healthcare, environmental, scientific research, industry and food sectors. Net sales (including intragroup) break down by family of products as follows: - medical diagnosis equipment (61%); - analytical tools and instruments (39%): biological molecular research tools, thermal analysis software, chemical and environmental measurement tools, genetic screening instruments, reagents, etc. Net sales are distributed geographically as follows: the United States (46.7%), China (14.4%), the United Kingdom (4.1%) and other (34.8%).

Employees

11,000

Sector

Advanced Medical Equipment & Technology

Calendar

Jul. 17 - Détachement de

More about the company